Single Nucleotide Polymorphisms Genotyping Market
Number of pages: 100 | Report Format: PDF | Published date: May 04, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
19.1% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Technology, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global single nucleotide polymorphisms genotyping market is expected to register a revenue CAGR of 19.1% during the forecast period.
Single Nucleotide Polymorphisms Genotyping Market Fundamentals
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation in the human genome. SNPs are single-base pair differences in DNA sequence that can occur within a population or between individuals. SNP genotyping is a technique used to identify and compare these genetic variations among individuals or populations. SNP genotyping involves the detection of the specific nucleotide at a particular SNP site. There are several techniques for SNP genotyping, including microarray-based genotyping, real-time PCR-based assays like TaqMan assays, and next-generation sequencing (NGS) methods.
In microarray-based genotyping, DNA samples are hybridized to a microarray containing probes specific to each SNP of interest. The hybridization pattern is then detected, and the sample's genotype is determined based on the signal intensity at each SNP site. In real-time PCR-based assays like TaqMan assays, DNA samples are amplified using PCR with specific primers that flank the SNP site of interest. A fluorescent probe specific to the allele of interest is then added, and the fluorescence signal is detected in real-time during PCR. The sample's genotype is determined based on the fluorescence signal at each SNP site.
Single Nucleotide Polymorphisms Genotyping Market Dynamics
Chronic diseases such as cancer, cardiovascular diseases, and diabetes are on the rise globally and are the primary driver for the growth of the global single nucleotide polymorphisms genotyping market. SNP genotyping is used extensively in research to identify genetic variations that may contribute to development of these diseases. Moreover, with the advent of newer technologies such as next-generation sequencing (NGS), microarray-based genotyping, and real-time PCR-based assays like TaqMan assays, the cost of SNP genotyping has reduced significantly. This has increased the adoption of these techniques in various research areas and diagnostics. Furthermore, with the advent of cloud computing, machine learning, and big data analytics, it has become easier to analyze large amounts of genotyping data quickly and efficiently. This has improved the accuracy and speed of SNP genotyping, making it more attractive to researchers and clinicians.
However, although the cost of SNP genotyping has reduced significantly in recent years, it is still relatively expensive compared to other genotyping techniques. This may limit the adoption of SNP genotyping in some research areas and clinical applications. Furthermore, the lack of standardized protocols and quality control measures for SNP genotyping can result in variations in results and make it difficult to compare data between different studies. This can limit the reliability and reproducibility of SNP genotyping results. Despite the growing adoption of SNP genotyping, there is still limited awareness among healthcare providers and researchers about the benefits of this technology. This can limit the demand for SNP genotyping and slow market growth.
Moreover, there are several alternative genotyping technologies, such as whole-genome sequencing and targeted sequencing, which can provide more comprehensive genetic information than SNP genotyping. These technologies could limit the adoption of SNP genotyping in some research areas and clinical applications. Additionally, competition from alternative technologies, limited awareness, and lack of standardization are some restraints impeding the overall market growth.
Single Nucleotide Polymorphisms Genotyping Market Ecosystem
The global single nucleotide polymorphisms genotyping market is analyzed from three perspectives: technology, application, and region.
Single Nucleotide Polymorphisms Genotyping Market by Technology
[258]
Based on the technology, the global single nucleotide polymorphisms genotyping market is segmented into SNP genechips and microarrays, TaqMan assay, SNP genotyping based upon pyrosequencing, sequenom massarray MALDI TOF, and others.
The SNP genechips and microarrays segment dominated the market with the principal revenue share in 2022. The SNP genechips and microarrays refer to using microarray-based genotyping to detect and analyze SNPs. SNP genechips and microarrays are platforms that contain thousands or millions of DNA probes specific to different SNPs of interest. The probes are arranged in a grid or array on a solid support, such as a glass slide or a microchip. These aspects contribute to the growth of the SNP genechips and microarrays segment.
The SNP genotyping based upon the pyrosequencing segment accounted for a prominent revenue share. SNP genotyping based on pyrosequencing offers several advantages over other genotyping methods. It is a highly accurate and reliable method with high sensitivity and specificity. It is also relatively fast and can analyze multiple SNPs simultaneously. It is also a flexible method that can be adapted for various applications, including diagnostic testing, pharmacogenomics, and research.
The sequenom masarray MALDI TOF based upon the pyrosequencing segment accounted for a significant revenue share. This technology is based on the principle of MALDI-TOF mass spectrometry, which is used to detect and quantify molecules based on their mass-to-charge ratio. The sequenom mass ARRAY platform uses a combination of PCR amplification and MALDI-TOF mass spectrometry to detect and genotype SNPs. In this process, DNA samples are first amplified using PCR with primers specific to the target SNP region. The resulting amplicons are then purified and spotted onto a silicon chip in a matrix of light-absorbing molecules. The chip is then subjected to laser energy, which causes the matrix to vaporize and release the target molecules. The molecules are ionized and accelerated through a time-of-flight mass spectrometer, separated by mass-to-charge ratio, and detected by a detector. The resulting mass spectra are used to determine the genotype of the target SNP.
Single Nucleotide Polymorphisms Genotyping Market by Application
Based on the application, the global single nucleotide polymorphisms genotyping market is segmented into animal genetics, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and others.
The pharmaceuticals and pharmacogenomics segment accounted for the largest revenue share of the market in 2022. The pharmaceuticals and pharmacogenomics segment refers to the use of SNP genotyping in the development and testing of drugs and pharmacogenomics research. Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. SNP genotyping can be used to identify genetic variations that affect drug metabolism and efficacy. This information can be used to guide drug development and optimize drug dosages. For example, SNP genotyping can identify genetic variations that affect the activity of drug-metabolizing enzymes, such as cytochrome P450 enzymes. This information can be used to develop more effective drugs with fewer side effects in individuals with specific genetic profiles. These factors contribute to the growth of the pharmaceuticals and pharmacogenomics segment.
The diagnostic research segment accounted for a prominent share of the market. The diagnostic research includes identifying genetic variants associated with disease risk, tracking the inheritance of genetic variants within families, and studying the genetic basis of complex traits. SNP genotyping is also used in pharmacogenomics, where it can be used to identify genetic variants that affect drug metabolism and treatment efficacy. This information can be used to guide personalized treatment plans, reduce the risk of adverse drug reactions, and optimize drug dosages. SNP genotyping can identify genetic variants that increase the likelihood of developing certain diseases, such as cancer or cardiovascular disease. This information can screen individuals for increased risk of developing these diseases and guide personalized treatment and prevention strategies. These factors contribute to the growth of the diagnostic research segment.
The animal genetics segment accounted for a significant share of the market. The animal genetics segment has a range of applications in the field of animal breeding, including livestock breeding, pet breeding, and conservation biology. In livestock breeding, SNP genotyping can be used to develop breeding programs that maximize the genetic potential of the animals. This can lead to increased production efficiency and profitability for farmers and producers. In pet breeding, SNP genotyping can identify potential health risks or hereditary diseases in certain breeds, allowing breeders to make informed decisions about which animals to breed. SNP genotyping can identify genetic markers associated with desirable animal traits, such as increased milk production or disease resistance. This information can then be used to select breeding pairs with the desired traits and improve the overall quality and health of the population.
Single Nucleotide Polymorphisms Genotyping Market by Region
Geographically, the global single nucleotide polymorphisms genotyping market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global single nucleotide polymorphisms genotyping market with the largest revenue share in 2022 due to the growing need for surgical automation, established competitors in the industry, technologically improved healthcare IT, and increased funding to upgrade OR infrastructure. Additionally, companies across the region are continuously involved in partnerships, mergers, and acquisitions, which are also expected to improve the single nucleotide polymorphisms genotyping market outlook. For instance, in August 2022,
Single Nucleotide Polymorphisms Genotyping Market Competitive Landscape
The prominent players operating in the global single nucleotide polymorphisms genotyping market are:
Single Nucleotide Polymorphisms Genotyping Market Strategic Developments
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation in the human genome. SNPs are single-base pair differences in DNA sequence that can occur within a population or between individuals.
The competition from alternative technologies, limited awareness, and lack of standardization restrict global market growth to its full potential.
The SNP genechips and microarrays technology segment accounts for the largest share of the global market.
The revenue CAGR of the single nucleotide polymorphisms genotyping market during the forecast period will be 19.1% from 2023 to 2031.
Some prominent players operating in the global single nucleotide polymorphisms genotyping market are GE Healthcare, Sequenom, Inc., Qiagen, Fluidigm Corporation, Agilent Technologies, and Thermo Fisher Scientific Inc.
*Insights on financial performance are subject to the availability of information in the public domain